touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer’s disease.
The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment with high-dose aducanumab in the Phase 3 study EMERGE” was presented at the Alzheimer’s Association International Conference (AAIC) 2021, 26th-30th July 2021.
ClinicalTrials.gov Identifier: NCT02484547
- Could you give us a brief overview of the clinical development of aducanumab in patients with early Alzheimer’s disease? (00:18)
- What was the rationale for this item-level analysis of clinical measures in the EMERGE clinical trial? (01:30)
- Which domains were analysed and what were the findings? (03:17)
- What have we learned from these findings and what were the conclusions of the investigators? (04:37)
- What will be the clinical impact of aducanumab on the treatment of patients with Alzheimer’s disease, and what does the future hold? (05:34)
Disclosures: Jeffrey Cummings has provided consultation to AB Science, Acadia, Alkahest, AlphaCognition, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Biohaven, Cassava, Cerecin, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, LSP, Merck, Novo Nordisk, Oligomerix, Ono, Otsuka, PRODEO, ReMYND, Renew, Resverlogix, Roche, Signant Health, Suven, United Neuroscience, and Unlearn AI pharmaceutical, assessment, and investment companies. Jeffrey Cummings owns the copyright of the Neuropsychiatric Inventory; and is supported by Alzheimer’s Drug Discovery Foundation (ADDF), NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053, and NIA grant R35AG71476.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the Alzheimer’s Association International Conference (AAIC) 2021.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Kristian Steen Frederiksen, EAN 2023: The new EAN guidelines
Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) summarizes some of the key updates to the EAN guidelines, and the take-home messages presented at the annual European Academy of Neurology (EAN), July 1–4, 2023. Disclosures: Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch […]
Kristian Steen Frederiksen, EAN 2023: Highlights in Alzheimer’s disease and dementia
Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) discusses his highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of Alzheimer’s disease and dementia. Disclosures:Kristian Steen Frederiksen has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming was supported by Touch Medical Media. The interview was conducted by Sophie Nickelson. […]
Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study
The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what the study found in terms of the effect of discrimination on the cognitive function of this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!